Fig. 1

The downregulation of YTHDC1 is associated with the poor prognosis in ccRCC. A, The expression level of YTHDC1 was analyzed by the ENCORI web tool in various types of solid tumor. P values and HR were indicated in the panel. B, The expression level of YTHDC1 in KIRC was analyzed by the Timer 2.0 (http://timer.cistrome.org/). *, P < 0.05. C, The prognosis of YTHDC1 in KIRC was determined by the ENCORI web tool. P values as indicated. D, CancerSEA web tool was used to analyze the biological function of YTHDC1 in the renal cell carcinoma. E-I, A498 and 786-O cells were transfected with indicated shRNAs for 72 h. After puromycin selection, cells were harvested for western blot analysis (E), RT-qPCR assay (F), CCK-8 assay (G), wound healing assay (H), transwell assay (I). Data presents as mean ± SD with three replicates. ***, P < 0.001. J-N, A498 and 786-O cells were transfected with indicated plasmids for 24 h. Cells were harvested for western blot analysis (J), RT-qPCR assay (K), CCK-8 assay (L), wound healing assay (M), transwell assay (N). Data presents as mean ± SD with three replicates. ***, P < 0.001